Blood-based biomarkers have expanded researchers’ ability to study Alzheimer’s disease without relying solely on brain imaging or cerebrospinal fluid analysis. The emerging eMTBR-tau biomarker could add a more direct measure of tau tangle pathology and help researchers assess disease stage, cognitive decline, and treatment response.
How eMTBR-Tau Differs From P-Tau217
eMTBR-tau and p-tau217 reflect different aspects of Alzheimer’s disease biology.
Steve Williams, chief scientific officer at Alamar Biosciences, explains that eMTBR-tau reflects the presence of physical tau tangles in the brain. These tangles form during the middle and later stages of Alzheimer’s disease and show a more consistent relationship with cognitive decline.
P-tau217 appears earlier in the disease process. It measures phosphorylated intact tau and can indicate amyloid accumulation before tau tangles and cognitive decline develop.
The two biomarkers may therefore provide complementary information. P-tau217 can help identify early pathological changes and amyloid accumulation, while eMTBR-tau can provide information about tau tangle burden and its relationship with cognition.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
“Thus, together, p217 and eMTBR can capture the range of stages, the two distinct components of Alzheimer’s disease and the relation with cognition that neither one alone can predict,” Williams explains.
Why eMTBR-Tau Is Difficult to Measure in Blood
eMTBR-tau occurs at very low concentrations in blood. Researchers therefore need assays with high sensitivity or must use extensive sample preparation before mass spectrometry can detect it.
The biomarker also presents a specificity challenge. eMTBR-tau represents a defined fragment of tau that results from cleavage at a consistent location within the full protein. An assay must distinguish that fragment from other tau forms in the sample.
Williams notes that “the combination of sensitivity and specificity has been difficult to establish for immunoassays.”
Potential Applications in Alzheimer’s Clinical Trials
A blood-based measurement of tau tangle pathology could support several parts of Alzheimer’s clinical trial design.
Researchers could use eMTBR-tau to select participants based on the relative contribution of amyloid and tau pathology. This approach could help match patients with trials that target a specific disease mechanism.
The biomarker could also support studies of therapies designed to reduce tau. Researchers could track baseline levels or changes in eMTBR-tau during treatment and compare them with cognitive outcomes.
Disease staging offers another potential use. Some trials focus on early disease, while others target later stages. A blood marker linked with tau tangle burden could help researchers classify participants with greater precision.
Researchers may also use the biomarker to enrich trials with participants who have a predicted rate of cognitive decline. Williams emphasizes that this approach could make studies shorter and more powerful.
Where Researchers May Use eMTBR-Tau First
Near-term adoption may begin through retrospective analysis of ongoing or completed clinical trials.
Researchers could compare baseline eMTBR-tau levels with cognitive response or examine changes in biomarker trajectory during a study. This approach would allow them to evaluate the biomarker without redesigning existing trial protocols.
Williams expects early adoption to combine therapy monitoring with patient stratification through post-hoc analysis of cognitive response against baseline eMTBR-tau levels or changes in biomarker trajectory during a study.
Evidence from these studies could then guide broader use in patient stratification, disease staging, and therapy monitoring. As blood-based biomarker panels expand, combining eMTBR-tau with markers such as p-tau217 may give researchers a more complete view of Alzheimer’s disease progression.
